With COVID-19 everyone's preeminent concern right now, structuring derivatives might seem a slightly facile way to spend your days. Working for a venture capital firm that makes biotechnology investments seems distinctly more relevant.
Pierre-Antoine Mudry spent over seven years at Goldman Sachs, where he was latterly an executive director in cross asset derivative structuring and sales in London. As of this month, however, Mudry has reinvented himself. He now works for Rejuveron Life Sciences in Switzerland instead.
In truth, Rejuveron isn't searching for a vaccine for the coronavirus and Mudry isn't on the frontline allocating money to promising cures. Rejuveron's stated purpose is, however, developing treatments and technologies, 'which have the potential to significantly prolong human lifespan,' and Mudry - as is typical of people from finance who move into these kinds of roles - is joining as a 'finance and operations lead.'
Mudry didn't respond to a request to comment on his move. As biotech funding takes off as a result of the pandemic, other people in finance may be interested in a similar shift. For the moment, Rejuveron is also hiring a Zurich-based head of business development with 10 years' experience in leading life sciences deals. Under-employed M&A bankers could always apply.
Have a confidential story, tip, or comment you’d like to share? Contact: firstname.lastname@example.org in the first instance. Whatsapp/Signal/Telegram also available. Bear with us if you leave a comment at the bottom of this article: all our comments are moderated by human beings. Sometimes these humans might be asleep, or away from their desks, so it may take a while for your comment to appear. Eventually it will – unless it’s offensive or libelous (in which case it won’t.)
Photo by ThisisEngineering RAEng on Unsplash